Solid tumor animal models and cellular experiments with bioinformatics research have demonstrated that blocking IL-27 signaling is beneficial for the treatment of hepatocellular carcinoma and renal cell carcinoma  (80, 81). This evidence concerns the gene IL27 and hepatocellular carcinoma.